TREVI THERAPEUTICS INC (TRVI) Fundamental Analysis & Valuation

NASDAQ:TRVI • US89532M1018

Current stock price

13.19 USD
-0.11 (-0.83%)
At close:
13.19 USD
0 (0%)
After Hours:

This TRVI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TRVI Profitability Analysis

1.1 Basic Checks

  • In the past year TRVI has reported negative net income.
  • TRVI had a negative operating cash flow in the past year.
  • In the past 5 years TRVI always reported negative net income.
  • TRVI had a negative operating cash flow in each of the past 5 years.
TRVI Yearly Net Income VS EBIT VS OCF VS FCFTRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • TRVI has a Return On Assets of -22.10%. This is comparable to the rest of the industry: TRVI outperforms 57.81% of its industry peers.
  • TRVI has a better Return On Equity (-23.33%) than 66.15% of its industry peers.
Industry RankSector Rank
ROA -22.1%
ROE -23.33%
ROIC N/A
ROA(3y)-32.61%
ROA(5y)-41.93%
ROE(3y)-35.54%
ROE(5y)-66.44%
ROIC(3y)N/A
ROIC(5y)N/A
TRVI Yearly ROA, ROE, ROICTRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

  • TRVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRVI Yearly Profit, Operating, Gross MarginsTRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TRVI Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, TRVI has more shares outstanding
  • The number of shares outstanding for TRVI has been increased compared to 5 years ago.
  • There is no outstanding debt for TRVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRVI Yearly Shares OutstandingTRVI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TRVI Yearly Total Debt VS Total AssetsTRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • TRVI has an Altman-Z score of 98.27. This indicates that TRVI is financially healthy and has little risk of bankruptcy at the moment.
  • TRVI has a Altman-Z score of 98.27. This is amongst the best in the industry. TRVI outperforms 97.92% of its industry peers.
  • TRVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 98.27
ROIC/WACCN/A
WACCN/A
TRVI Yearly LT Debt VS Equity VS FCFTRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 19.66 indicates that TRVI has no problem at all paying its short term obligations.
  • TRVI's Current ratio of 19.66 is amongst the best of the industry. TRVI outperforms 91.67% of its industry peers.
  • TRVI has a Quick Ratio of 19.66. This indicates that TRVI is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TRVI (19.66) is better than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 19.66
Quick Ratio 19.66
TRVI Yearly Current Assets VS Current LiabilitesTRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TRVI Growth Analysis

3.1 Past

  • TRVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.91%, which is quite impressive.
EPS 1Y (TTM)31.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, TRVI will show a very strong growth in Earnings Per Share. The EPS will grow by 41.17% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-50.39%
EPS Next 2Y-34.92%
EPS Next 3Y-17.67%
EPS Next 5Y41.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRVI Yearly Revenue VS EstimatesTRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
TRVI Yearly EPS VS EstimatesTRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. TRVI Valuation Analysis

4.1 Price/Earnings Ratio

  • TRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRVI Price Earnings VS Forward Price EarningsTRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRVI Per share dataTRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • A cheap valuation may be justified as TRVI's earnings are expected to decrease with -17.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.92%
EPS Next 3Y-17.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRVI Dividend Analysis

5.1 Amount

  • TRVI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRVI Fundamentals: All Metrics, Ratios and Statistics

TREVI THERAPEUTICS INC

NASDAQ:TRVI (4/10/2026, 8:00:01 PM)

After market: 13.19 0 (0%)

13.19

-0.11 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-17
Earnings (Next)05-06
Inst Owners93.63%
Inst Owner Change0%
Ins Owners0.76%
Ins Owner Change0%
Market Cap1.69B
Revenue(TTM)N/A
Net Income(TTM)-42.76M
Analysts85.56
Price Target21.93 (66.26%)
Short Float %14.45%
Short Ratio11.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.16%
Min EPS beat(2)20.24%
Max EPS beat(2)40.09%
EPS beat(4)4
Avg EPS beat(4)25.03%
Min EPS beat(4)12.64%
Max EPS beat(4)40.09%
EPS beat(8)5
Avg EPS beat(8)8.53%
EPS beat(12)9
Avg EPS beat(12)11.35%
EPS beat(16)13
Avg EPS beat(16)14.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.98%
PT rev (3m)1.98%
EPS NQ rev (1m)33.48%
EPS NQ rev (3m)33.48%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.23
P/tB 9.23
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS1.43
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.1%
ROE -23.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.61%
ROA(5y)-41.93%
ROE(3y)-35.54%
ROE(5y)-66.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.66
Quick Ratio 19.66
Altman-Z 98.27
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)47.84%
Cap/Depr(5y)108.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y-50.39%
EPS Next 2Y-34.92%
EPS Next 3Y-17.67%
EPS Next 5Y41.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.4%
EBIT Next 3Y-32.44%
EBIT Next 5Y15.29%
FCF growth 1Y-9.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.02%
OCF growth 3YN/A
OCF growth 5YN/A

TREVI THERAPEUTICS INC / TRVI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TREVI THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRVI.


Can you provide the valuation status for TREVI THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to TREVI THERAPEUTICS INC (TRVI). This can be considered as Overvalued.


What is the profitability of TRVI stock?

TREVI THERAPEUTICS INC (TRVI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for TRVI stock?

The Earnings per Share (EPS) of TREVI THERAPEUTICS INC (TRVI) is expected to decline by -50.39% in the next year.